News

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of…

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk…

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-…

Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in…

The PAN Foundation helps people living with life-threatening, chronic, and rare diseases with financial help for out-of-pocket treatment costs. Join to learn about…

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics…

The year is flying by and you are invited to a Christmas morning tea in December.The venue, time and place is, as always, set out on the right. I am really looking…

In its native tetrameric form, transthyretin (TTR) protein, which is primarily produced in the liver, serves as a carrier for thyroxin and retinol binding protein […

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can…